Clinical Trials Network - Network Organization

Skip Navigation

NIDA NEWS

The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse

Search the NIDA website

Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Two Schedules (CTN 0003)

Enrollment (Complete)

Description

For decades clinicians have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs (NTPs). A new medication, buprenorphine, shows promise as an effective aid for opiate detoxification. However, little data have been generated for the shorter-term use of buprenorphine/naloxone for this indication. This protocol will compare the clinical utility of two dosage tapering regimens in buprenorphine/naloxone stabilized subjects for opiate detoxification.

For further information on clinical trials, click here.

Available Brochures

Patient Brochure	.PDF

You need Adobe Acrobat Reader in order to view the .pdf file.
Acrobat Reader can be downloaded for free from www.adobe.com.

Principal Investigator :

Walter Ling, M.D.
E-Mail : lwalter@ix.netcom.com
Phone : (310) 312-0500

NODES & CTPs:

Pacific Region Node (Lead)

Long Island Node
North Shore - Long Island Jewish Health System

New England Node
Connecticut Counseling Centers, Inc.
Hartford Dispensary

New York Node
VA New York Harbor Healthcare System

North Carolina Node
Coastal Horizons Center, Inc.
SouthLight, Inc.

Oregon/Hawaii Node
CODA, Inc.

Pacific Northwest Node
Providence Behavioral Health Service

Rocky Mountain Regional Node
Addiction Research and Treatment Services
Denver Health and Hospital Authority

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Thursday, June 26, 2008.